Suppr超能文献

基于稳定同位素的非酒精性脂肪性肝病通量研究。

Stable isotope-based flux studies in nonalcoholic fatty liver disease.

机构信息

Department of Gastroenterology & Hepatology, Cleveland Clinic, Cleveland, OH, USA.

Merck & Co., Inc., Kenilworth, NJ, USA.

出版信息

Pharmacol Ther. 2018 Jan;181:22-33. doi: 10.1016/j.pharmthera.2017.07.008. Epub 2017 Jul 16.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is associated with the worldwide epidemics of obesity, diabetes and cardiovascular diseases. NAFLD ranges from benign fat accumulation in the liver (steatosis) to non-alcoholic steatohepatitis (NASH), and cirrhosis which can progress to hepatocellular carcinoma and liver failure. Mass spectrometry and magnetic resonance spectroscopy-coupled stable isotope-based flux studies provide new insights into the understanding of NAFLD pathogenesis and the disease progression. This review focuses mainly on the utilization of mass spectrometry-based methods for the understanding of metabolic abnormalities in the different stages of NAFLD. For example, stable isotope-based flux studies demonstrated multi-organ insulin resistance, dysregulated glucose, lipids and lipoprotein metabolism in patients with NAFLD. We also review recent developments in the stable isotope-based technologies for the study of mitochondrial dysfunction, oxidative stress and fibrogenesis in NAFLD. We highlight the limitations of current methodologies, discuss the emerging areas of research in this field, and future directions for the applications of stable isotopes to study NAFLD and its complications.

摘要

非酒精性脂肪性肝病(NAFLD)是最常见的慢性肝病,与肥胖症、糖尿病和心血管疾病在全球的流行密切相关。NAFLD 的范围从肝脏的良性脂肪堆积(脂肪变性)到非酒精性脂肪性肝炎(NASH)和肝硬化,后者可进展为肝细胞癌和肝功能衰竭。质谱和磁共振波谱-偶联稳定同位素通量研究为理解 NAFLD 的发病机制和疾病进展提供了新的见解。本综述主要侧重于利用基于质谱的方法来理解 NAFLD 不同阶段的代谢异常。例如,基于稳定同位素的通量研究表明,NAFLD 患者存在多器官胰岛素抵抗、葡萄糖、脂质和脂蛋白代谢失调。我们还回顾了基于稳定同位素的技术在研究 NAFLD 中线粒体功能障碍、氧化应激和纤维化方面的最新进展。我们强调了当前方法学的局限性,讨论了该领域新兴的研究领域,以及将稳定同位素应用于研究 NAFLD 及其并发症的未来方向。

相似文献

1
Stable isotope-based flux studies in nonalcoholic fatty liver disease.基于稳定同位素的非酒精性脂肪性肝病通量研究。
Pharmacol Ther. 2018 Jan;181:22-33. doi: 10.1016/j.pharmthera.2017.07.008. Epub 2017 Jul 16.
10
Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病
Adv Exp Med Biol. 2017;960:443-467. doi: 10.1007/978-3-319-48382-5_19.

引用本文的文献

5
Triglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent.非酒精性脂肪性肝病中的甘油三酯:无罪推定。
Trends Pharmacol Sci. 2021 Mar;42(3):183-190. doi: 10.1016/j.tips.2020.12.001. Epub 2021 Jan 16.
8
HDL flux is higher in patients with nonalcoholic fatty liver disease.非酒精性脂肪肝患者的高密度脂蛋白通量较高。
Am J Physiol Endocrinol Metab. 2019 Nov 1;317(5):E852-E862. doi: 10.1152/ajpendo.00193.2019. Epub 2019 Sep 10.

本文引用的文献

8
Natural History of Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病的自然史
Dig Dis Sci. 2016 May;61(5):1226-33. doi: 10.1007/s10620-016-4095-4. Epub 2016 Mar 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验